Frontlight ResearchEarly access
TerminatedNo phase
Oxygen Therapy in Patients With Chronic Heart Failure With Reduced Ejection Fraction
Key facts
- Who runs it
- Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
- Where
- Spain1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 1 person enrolled
- Started
- 1 Jul 2022
- Ended
- 31 Jul 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Oxygen Therapy
- Record updated
- 8 October 2024
- Why it stopped
- Difficulty in recruitment
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (10)Hide the full registry criteria
Who can take part
- Patients > 18 years old
- Diagnosis and clinic of chronic heart failure with ventricular dysfunction with left ventricular ejection fraction (LVEF) <40% under optimal medical treatment regardless of its etiology and having presented at least one episode of decompensation (visits to the emergency room, hospitalizations and/or need for intravenous depletive treatment) during the last year
- Nocturnal desaturation defined as mean SatO2 <90% and/or Cummulative time (TC) <90>22 minutes to nocturnal pulse oximetry done at home
- Signed informed consent
Who cannot take part
- Previous treatment with oxygen therapy
- Chronic lung disease (includes chronic obstructive pulmonary disease with Pulmonary respiratory function (PRF) (forced expiratory volume at one second/forced vital capacity (FEV1/FVC) <70%), diffuse interstitial diseases, pulmonary hypertension of respiratory)
- Obstructive sleep apnea-hypopnea syndrome (OSAHS) with Apnea hypopnea index (AHI) > 14.9
- Not agreeing to attend periodic cardiology visits
- Being part of other clinical studies that contraindicate an intervention
- Pregnant or breastfeeding women
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to assess patients with chronic heart failure and moderate-severe ventricular dysfunction (left ventricular ejection fraction (FEVE) <40%) with nocturnal desaturation (mean Oxygen saturation (SatO2) <90% and/or Cummulative time (TC) <90% > 22 minutes) without underlying respiratory disease, oxygen treatment during hours of night rest will reduce exacerbations, improve the ability to effort, sleep quality and poor prognostic parameters of heart failure, compared to patients not receiving oxygen treatment.
The 2 groups in the trial
- Oxygen TherapyExisting treatment, for comparison
Participants received nocturnal oxygen therapy (minimum 6 hours) for 6 months.
- No Oxygen TherapyNo study treatment, for comparison
Participants will not received oxygen therapy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Impact of Oxygen Therapy on Readmissions of Patients With Chronic Heart Failure With Reduced Ejection Fraction
- Record updated
- 8 October 2024